Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BDA202206

Anti-B7H3 ADC

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: Anti-B7H3 ADC
    Indications: Broad cancer
    Research phase: PCC
    Cooperation demands: License-out or co-development the global right
  • Highlights

    1. Clear MOA


    (1) The B7H3 protein (encoded from the CD276 gene) is a checkpoint molecule that is highly expressed in solid tumors, with reportedly limited expression in normal tissues. Overexpression of B7H3 is correlated with tumor progression, metastasis, and poor clinical outcome across a variety of malignancies.


    (2) Monoclonal antibodies targeting B7H3 cause limited toxicity and have demonstrated some anti-tumor activity in clinical trials. Anti-B7H3 ADC can get better anti-tumor effect than anti-B7H3 mAb.


    2. Antibodies specific binding to human B7H3 protein


    Both anti-B7H3 are strong in binding to human B7H3. And anti-B7H3 #2’s affinity to mouse B7H3 is 100-fold weaker than Human B7H3.


    3. High selectivity and affinity


    (1) Both anti-B7H3’s cell-based affinity binding of 1-2 digit nano-molar was observed across cell lines. And No non-specific binding was observed on a target-negative cell line.


    (2) No non-specific binding to other family members.


    4. Induced strong B7H3 internalization on tumor cells.


    5. Anti-B7H3 ADC showed strong potency in target-expressing cell lines, but weak potency in target-negative cell line, comparable to the isotype control ADC.


    6. Good thermostability

  • Project Introduction

    1. Asset type: Anti-B7H3 ADC, 2 antibody sequences

    2. Indication: Broad cancer

    3. Modality: Small molecular

    4. Research phase: Phase 1, IP has been granted in US, AU, CN

    5. Cooperation demands: License-out or co-development

    6. Research progress:

    (1) Anti-B7H3 #2 (MMAE) ADC showed strong potency in target-expressing cell lines. Potency on a target-negative cell line was minimal and comparable to the isotype control ADC.
    (2) Camptothecin ADCs: DAR8 conjugation was achieved. Both, Anti-B7H3 #1 and #2, showed some differential potency as Camptothecin ADCs over isotype control ADC in Calu-6 and HEC-251 cells.

Comments (0)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message